Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related
metabolic syndrome. The condition is often poorly treated and may lead to the emergence of
coronary heart disease and type 2 diabetes. The study will investigate whether structured
treatment provided at the site of the outpatient psychiatric clinic of metabolic syndrome in
this population will decrease the severity of metabolic syndrome as compared with usual care
received by these patients in the community.